We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Joint FDA Panel Backs Safety of Drospirenone Contraceptives
Joint FDA Panel Backs Safety of Drospirenone Contraceptives
December 16, 2011
A joint FDA advisory panel has concluded that the benefits of drospirenone birth control outweigh the increased risk of blood clots, saying data from various observational postmarket clinical trials are too conflicting and the risks, in any case, are rare among drospirenone users.